- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03489746
Steroid Withdrawal Intervention in Fife and Tayside (SWIFT)
A Cluster Randomised Trial of Medication Review and Withdrawal of Inappropriate Inhaled Corticosteroid Treatment in Chronic Obstructive Pulmonary Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide and a major cause of morbidity in the UK. Inhaled corticosteroids (ICS) are frequently prescribed to patients with COPD and these medications represent a major burden on the National Health Service in terms of drug costs. They are not without side effects, and pneumonia in particularly has been highlighted as a common adverse event in COPD patients receiving ICS.
In the UK, inhaled corticosteroids are indicated for patients with severe or very severe COPD (Forced expiratory volume in 1 second <50% predicted) who experience frequent exacerbations. International guidelines and strategies such as those from Global Obstructive Lung Disease (GOLD), also suggest inhaled corticosteroids should be reserved for patients with frequent exacerbations despite appropriate treatment with inhaled bronchodilators such as combined long acting beta-agonists and long acting muscarinic antagonists (LABA/LAMA combinations). Despite this guidance, use of inhaled corticosteroids in patients with milder COPD and without a history of exacerbations is common. Randomised controlled trials suggest that inhaled corticosteroids can be withdrawn from COPD patients with minimal adverse effects. Attempts to reduce inappropriate ICS prescribing have been largely unsuccessful in real-life, however, because of "non-evidence barriers". These include a lack of expertise in general practice to identify patients suitable for ICS withdrawal, fear of adrenal insufficiency, concern about missing a diagnosis of asthma and time. A high proportion of COPD care in the United Kingdom is delivered by specialist practice nurses, who may not be empowered to withdraw ICS in the absence of specific guidance or protocols.
The SWIFT trial is a cluster randomised trial to determine if a patient identification, feedback and ICS withdrawal intervention in primary care can result in more appropriate inhaled corticosteroid use without increasing the frequency of exacerbations. Practices in Tayside and Fife will be randomised at practice level to an intervention or control. The intervention will consist of electronic review of patients COPD data and prescribing history, followed by implementation of a medication change involving withdrawal of ICS and introduction of a LABA/LAMA for patients without an indication for ongoing ICS treatment. Patients in control practices will not receive the intervention, but practices will be provided with local guidelines and formulary and encouraged to prescribe appropriately. Patients in the control practices may be switched to guideline compliant medications (which may include the withdrawal of inhaled corticosteroids).
Our hypothesis is that the above "non-evidence barriers" will result in an ongoing high inappropriate use of ICS in control practices while an intervention that overcomes these will result in high rates of ICS withdrawal and that the intervention will be safe, as evidenced by no increase in the frequency of exacerbations over 12 months of follow-up.
This study will make an important contribution to understanding the role of inhaled corticosteroids in COPD. If successful, the intervention could be safely applied throughout the NHS to reduce inappropriate medication use, reduce patient side effects and healthcare costs.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Kirkcaldy, United Kingdom
- NHS FIFE
-
-
Perthshire
-
Dundee, Perthshire, United Kingdom, DD1 9SY
- NHS Tayside
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female patients aged > 40 years
- A clinical diagnosis of COPD made by a physician
- Post-bronchodilator FEV1/FVC ratio at screening of <70%
Exclusion Criteria:
- Asthma recorded in general practice records or clinically suspected
- Patients with COPD receiving inhaled short acting beta-2 agonist only.
- Residence outwith Tayside and Fife
- Insufficient data available to determine appropriateness of ICS and other medication use.
- Known previous failure of inhaled corticosteroid withdrawal
- Patients should be excluded if, in the opinion of the practice, making changes to their current COPD treatment regime is not in the patients best interests.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Inhaled corticosteroid withdrawal
Patients meeting the study criteria for withdrawal will have their ICS containing regime changed to a LABA/LAMA regime without ICS.
|
A primary care intervention to support switch from ICS containing regimen to non-ICS containing regimen in appropriate patients.
|
Active Comparator: Standard care
Patients will continue on their current recommended regimen including ICS.
|
Normal clinically indicated inhaled therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of moderate and severe exacerbations of COPD
Time Frame: 1 year
|
Use of corticosteroids and/or antibiotics (moderate) or hospitalization (severe) for exacerbation of COPD
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Respiratory Hospitalizations
Time Frame: 1 year
|
1 year
|
|
Success of ICS withdrawal
Time Frame: 1 year
|
Inhaled corticosteroid prescribing rates (number of patients receiving inhaled corticosteroid prescriptions at study completion divided by total number of COPD patients) and withdrawal rates (number of patients receiving inhaled corticosteroids prior to the intervention divided by the number of patients receiving inhaled corticosteroids following the intervention in each arm)
|
1 year
|
Time to the first moderate and severe exacerbation
Time Frame: Time to first event (patients without an event censored at 1 year)
|
First exacerbation or respiratory hospitalisation following the intervention
|
Time to first event (patients without an event censored at 1 year)
|
Oral corticosteroid use
Time Frame: 1 year
|
Cumulative prescriptions for oral corticosteroids (excluding chronic low dose oral corticosteroids)
|
1 year
|
Antibiotic use
Time Frame: 1 year
|
Cumulative prescriptions for oral antibiotics (excluding chronic low dose macrolides)
|
1 year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rates of known ICS related adverse effects between groups
Time Frame: 1 year
|
Pneumonia, fractures, cataracts and diabetes
|
1 year
|
Rates of ICS relapse
Time Frame: 1 year
|
Proportion of patients undergoing ICS withdrawal who are subsequently restarted on inhaled corticosteroids within 12 months
|
1 year
|
Mortality
Time Frame: 1 year
|
GRO based mortality data
|
1 year
|
Subgroup analyses in patients successfully withdrawing ICS
Time Frame: 1 year
|
Frequency of moderate and severe exacerbations
|
1 year
|
Subgroup analyses based on baseline lung function for major endpoints
Time Frame: 1 year
|
Frequency of moderate and severe exacerbations
|
1 year
|
Subgroup analyses based on baseline eosinophil count <300 cells/ul for major endpoints
Time Frame: 1 year
|
Frequency of moderate and severe exacerbations
|
1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Philip M Short, NHS Tayside
- Principal Investigator: Devesh Dhasmana, NHS FIFE
- Study Director: Arlene Shaw, NHS Tayside
- Study Director: Fiona Eastop, NHS Tayside
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2016RC23
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on ICS withdrawal protocol
-
Radboud University Medical CenterNovartis; Boehringer IngelheimUnknownPulmonary Disease, Chronic ObstructiveNetherlands
-
Neuromed IRCCSRecruiting
-
Rabin Medical CenterUnknown
-
NorthShore University HealthSystemCompleted
-
Changhai HospitalShaanxi Provincial People's Hospital; Qinghai People's Hospital; The First Affiliated... and other collaboratorsCompleted
-
Washington University School of MedicineTerminatedColorectal Cancer | Rectal Cancer | Colon CancerUnited States
-
Nanjing UniversityUnknownInfertile High-risk Patients With Polycystic OvariesChina
-
The Catholic University of KoreaCompletedAdenoma of Large Intestine
-
Incyte CorporationRecruitingModerate to Severe AsthmaKorea, Republic of, United States, Spain, Poland, Japan, Canada, Germany, Belgium, Argentina
-
Assiut UniversityNot yet recruiting